About Nelson+
A platform built for population-based lung cancer screening
Originally developed for the NELSON trial and now used in live screening services, the platform supports the full pathway from cohort identification to long-term follow-up and national reporting.
Who Are We
Nelson+ is a dedicated platform for the programme-level delivery of lung cancer screening.
Developed from the NELSON trial and used in live clinical services, it enables safe, scalable and fully auditable pathway management.
Our Mission
To enable healthcare organisations to deliver lung cancer screening efficiently and at scale through a clinically validated, deployment-ready platform.
An integrated screening ecosystem
RADventure operates within a closely connected ecosystem of organisations, each contributing a critical part of the screening pathway.
A dedicated lung cancer screening platform developed by RADventure. Nelson+ is used in live screening programmes including research trials and national LCS programmes.
Designs and delivers population
based screening platforms used in real world clinical settings, national programmes and international research initiatives.
A clinical research organisation focused on advancing lung cancer screening worldwide. iDNA contributes expertise in study design, evidence generation and international implementation.
Leadership & commercial team
Nelson+ is led by a management team with deep roots in population-based screening. Our managing director brings more than 20 years of hands-on experience in designing and delivering screening programmes.
The technical leadership team combines over two decades of individual expertise in screening systems and large-scale programme delivery. Together with a wider organisation of more than 35 specialists, the team brings hundreds of years of combined experience across screening operations, clinical research and software development.
As Nelson+ is a wholy owned subsidiary of RADventure, the full team and organisational structure can be viewed at the RADventure website.